Introduction: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the proliferation of progenitor cells of the myeloid lineage, increasing the circulating cells of the granulocytic lineage. The annual incidence of CML is 1 to 2 cases per 100,000 individuals, representing about 15% to 20% of leukemias. The Northern region of Brazil has the lowest percentage of hospitalizations due to leukemia (6.3% of the national total), which may indicate challenges in access to diagnosis and treatment. Objectives: To analyze the status of the BCR-ABL gene transcript in CML cases in patients from the Brazilian Amazon in relation to frequency and association with known prognostic laboratory data. Methods: The research included a total of 162 patients detectable for one of the BCR-ABL gene transcripts between January 2015 and December 2024. Laboratory data on leukocyte count, platelet count, sex and age were collected from the HEMOPA Foundation database system. For the analysis of fusion transcripts, c-DNA was obtained for the detection of the presence of molecular biomarkers by Real-Time PCR (RT-qPCR) using specific Taqman probes on the Rotor Gene equipment. For qualitative variables, descriptive statistics were used, determining absolute and percentage frequencies. For quantitative variables, mean and median values, standard deviation, and maximum and minimum values were calculated according to the variables under study. The Kruskal-Wallis test was performed to test the association of the presence of one of the BCR-ABL gene transcripts (B2A2, B3A2, and/or B2A2/B3A2) with laboratory data, adopting a p-value ? 0.05 as significant. Statistical analyses were performed using SPSS 29.0 software. The study presents CEP-CAEE 20528519.8.0000.5550. Results: Regarding the BCR-ABL gene, 39.5% (64/162) presented the B2A2 transcript, 27.8% (45/162) presented B3A2, and 32.7% (53/162) presented B2A2/B3A2. As for sex, 59.3% (96/162) were male and 40.7% (66/162) were female, and the median age of the patients was 45.5 years. Regarding leukocyte count, patients had a median of 143,500/mm³; as for platelet count, the median was 388,500/mm³. The Kruskal-Wallis test revealed that there is no statistical difference between the types of BCR-ABL gene fusion transcript and the laboratory data on leukocyte and platelet counts. Conclusion: The B2A2 transcript was observed as the most prevalent among CML patients, and patients with this type of transcript had a higher median leukocyte count compared to other groups. Patients with the B3A2 transcript had a higher median platelet count compared to others; however, in both analyses, no significant difference was found between the groups. The transcript has an impact on the disease development process, potentially leading the patient to produce many cells. Therefore, it is worthwhile to study the BCR-ABL gene pathways and find new treatment strategies.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
